Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers

Tue. October 27, 2009; Posted: 08:00 AM
Stocks RSS
INDIANAPOLIS, Oct 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- LLY | Quote | Chart | News | PowerRating -- Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year.(1) It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.(1) Still, lung cancer lags far behind other cancers in both awareness and research funding, and, partly due to its connection with smoking, there can be a stigma attached to the disease.(2)

But there is hope for lung cancer patients. According to Richard Gaynor, M.D., vice president of oncology product development and medical affairs at Eli Lilly and Company, a leader in thoracic cancer treatment, "Researchers have made important strides in the last decade in lung cancer prevention, detection and treatment. We know that secondary smoke is detrimental.(3) We have better X-rays and spiral CT scans to detect lung cancer earlier on. And we know that where treatment is concerned, lung cancer, like breast cancer, can benefit from a tailored approach."

In the past, oncologists have used similar approaches to treatment based on lung cancer diagnosis, staging and prognosis.(4) But advances in tailored treatment options may help oncologists choose which patients could be more likely to benefit from certain therapies.

"While our work is far from finished, we do have a better understanding of lung cancer today, and patients can benefit," said Dr. Gaynor.

Prevalence and Prognosis

Lung cancer can affect any adult, including nonsmokers. Since 1985, it has risen to be the world's most common form of cancer, and an estimated 219,440 more Americans are expected to be diagnosed this year.(5) The chance that a man will develop lung cancer is about 1 in 13, and for a woman it is approximately 1 in 16.(1) Nearly 70 percent of people diagnosed with lung cancer are older than 65; fewer than three percent of all cases are found in people under the age of 45.(6)

Survival is improved the earlier a patient is diagnosed with lung cancer. With early detection, there is a 50 percent chance of surviving for five years. However, only 16 percent of cases are diagnosed at an early stage. Unfortunately, as the disease is often diagnosed at later stages, approximately 59 percent of those with lung cancer will die within the first year of diagnosis.(7)

The five-year survival rate for lung cancer has increased slightly over the last 30 years. In the mid-1970s the rate was 13 percent, as compared to the latest statistics which find the rate at 15.6 percent for the years 1999 - 2006.(8)

Symptoms

In the early stages of the disease, many people have vague or no symptoms. Persistent cough along with blood in the phlegm and shortness of breath are common symptoms of lung cancer. Sometimes, symptoms may seem unrelated to the lungs or breathing. As lung cancer is diagnosed mostly in later stages, the primary cancer may have already spread to other parts of the body. Depending upon where the cancer spreads and which organs are affected, symptoms may also include headaches, weakness of a limb, bone pain, weight loss and loss of appetite.(9)

If You are Diagnosed: What to Ask Your Oncologist(10)

    --  What kind of lung cancer do I have?
    --  Has my cancer spread beyond my lungs, or is it limited to my lungs only?
    --  What is the stage of my cancer, and what does that mean in my case?
    --  Are there other tests that need to be done before we can decide on
        treatment?
    --  What treatment choices do I have?
    --  What risks or side effects are there to the treatments you suggest?
    --  How long will treatment last?  What will it involve?  Where will it be
        done?
    --  What are the chances of recurrence of my cancer after treatment?  And
        what treatments are available if it recurs?

    --  Am I eligible for clinical trial?

For more information on the signs and symptoms of lung cancer, diagnostics and treatment options, please see your qualified healthcare professional.

About Lilly Oncology, a Division of Eli Lilly and Company

For more than four decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. Our quest is to develop a broad portfolio of tailored therapies that accelerate the pace and progress of cancer care. To learn more about Lilly's commitment to cancer, please visit www.LillyOncology.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

(1) American Cancer Society, "What Are the Key Statistics About Lung Cancer?," October 24, 2008, American Cancer Society, http://www.cancer.org/docroot/CRI/content/CRI_2_4_1x_What_Are_the_Key_Statistics_About_Lung_Cancer_15.asp?sitearea, (September 1, 2009).

(2) Lung Cancer Alliance, "2009 Facts About Lung Cancer," Lung Cancer Alliance, www.lungcanceralliance.org/pdf_docs/2009_Factsheet.pdf, (October 14, 2009).

(3) American Cancer Society, "Secondhand Smoke," May 22, 2009, American Cancer Society, http://www.cancer.org/docroot/PED/content/PED_10_2X_Secondhand_Smoke-Clean_Indoor_Air.asp, (September 30, 2009).

(4) National Cancer Institute, "Non-Small Cell Lung Cancer Treatment (PDQ(R)) Health Professional Version," July 10, 2009, National Cancer Institute, www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/HealthProfessional/page2, (September 1, 2009).

(5) American Cancer Society, "How Many People Get Non-small Cell Lung Cancer?" 2009, American Cancer Society, http://www.cancer.org/docroot/CRI/content/CRI_2_2_1x_How_Many_People_Get_Non-small_Cell_Lung_Cancer.asp?sitearea= , (October 14, 2009).

(6) American Cancer Society, "What Are the Key Statistics for Small Cell Lung Cancer?." October 30, 2008, American Cancer Society, http://www.cancer.org/docroot/CRI/content/CRI_2_4_1x_What_Are_the_Key_Statistics_for_Small_Cell_Lung_Cancer.asp?sitearea, (September 1, 2009).

(7) American Cancer Society, "Cancer Facts & Figures 2009," Atlanta: 2009, www.cancer.org/docroot/STT/STT_0.asp, (October 8, 2009).

(8) National Cancer Institute, "Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program," National Cancer Institute, http://seer.cancer.gov/statfacts/html/lungb.html, (September 1, 2009).

(9) American Cancer Society, "How Is Non-Small Cell Lung Cancer Diagnosed?." October 24, 2008, American Cancer Society, http://www.cancer.org/docroot/CRI/content/CRI_2_4_3x_How_Is_Non-Small_Cell_Lung_Cancer_Diagnosed.asp?sitearea=, (October 20, 2009).

(10) American Cancer Society, "What Should You Ask Your Doctor About Non-Small Cell Lung Cancer?," October 24, 2008, American Cancer Society, http://www.cancer.org/docroot/CRI/content/CRI_2_4_5x_What_Should_You_Ask_Your_Doctor_About_Non-Small_Cell_Lung_Cancer.asp?sitearea=, (September 30, 2009).

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

CR-LLY

SOURCE Eli Lilly and Company

http://www.lilly.com
For full details on Eli Lilly & Company (LLY) click here. Eli Lilly & Company (LLY) has Short Term PowerRatings of 5. Details on Eli Lilly & Company (LLY) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [LLY]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.